Test Directory

MYD88 p.L265P Mutation testing

Containers - Adult

RedCapTubeEDTAKE2.7ml.jpg
Red Cap Tube EDTA KE 2.7ml
Volume Range

​5ml peripheral blood, bone marrow specimen or FFPE tissue

Additive per Container

​EDTA

path_block_slide.jpg
FFPE block / H&E slide / Pathology report

Laboratory Site

WGH
Crewe Road South
Edinburgh
EH4 2XU
Telephone: 0131 537 1000

Transport arrangements

Blood and bone marrow specimens should ideally arrive within 24 hours of collection (maximum of 48 hours).  There is no time limit for FFPE samples.  Samples should be sent to the following address:

Western General Hospital

Haematology/Biochemistry Combined Reception

Immunophenotyping Laboratory

Crewe Road

Edinburgh

EH4 2XU​

 

See also Specimen transportation.

Sample storage arrangements

Samples should be stored at room temperature. See specimen requirements.​

How to request

Please refer to our detailed requesting ​instructions.  The HMDS request form can be located here.​

 

Requests for testing FFPE tissue should be sent to the Molecular Pathology Service at RIE with a completed HMDS test request form. 

Availability

​Monday-Friday 9am-5pm

Anticipated turnaround

Results should be expected within 10 working days.  See results.

Static information/disclaimer

All sample with a CLL score <2 via Immunophenotyping will be tested for MYD88 p.L265P mutations via a reflex testing strategy

General additional information

This test uses an allele specific real time PCR for the identification of the MYD88 p.L265P variant to help aid in the differentiation of low grade B Cell lymphoplasmacytic lymphoma (LPL), Waldenström Macroglobulinaemia (WM) and IgM monoclonal gammopathy of undetermined significance (MGUS) from marginal zone lymphomas. The MYD88 p.L265P mutation can also be used to distinguish the different sub-types of diffuse large B cell lyphomas (DLBCL); the L265P mutation being found in activated B cell like DLBCL, but rarely in the germinal centre like DLBCL. See testing.

This test is accredited to ISO 15189:2012

For clinical advice on appropriate investigations and advice for the interpretation of test results, please see contact us​.